The team at Johns Hopkins In-Vivo Cellular and Molecular Imaging Center in Baltimore is using novel imaging tools to discover new early detection methods for cancers existing in cells, and study its prevention and elimination before spreading to other organs and tissues.

Seegene has entered a partnership with Samsung Medical Center to co-develop molecular diagnostics for cancer.

Contrast-enhanced ultrasound imaging with molecularly targeted microbubbles allowed noninvasive in vivo assessment of a_vB₃ integrin, endoglin and vascular endothelial growth factor receptor 2 expression levels, which vary during tumor growth in subcutaneous cancer xenografts, based on a mouse model study in the March issue of Radiology. The researchers suggested their results may help define promising imaging targets for both early cancer detection and treatment monitoring.